# Program 06 Lymphoma and Myeloma

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2022 · $41,711

## Abstract

Lymphoma and Myeloma Program
Project Summary / Abstract
The Lymphoma and Myeloma Program characterizes specific lymphoid and plasma cell malignancies at the
cellular and molecular level using state-of-the-art approaches, including informative murine models, patient
tumors, and comprehensive analyses of molecular signatures. Program members then translate the emerging
insights into innovative clinical trials. Members include: 1) investigators with lymphoma and myeloma research
programs that span basic, translational and clinical research; 2) dedicated clinicians; 3) hematopathologists;
and 4) computational biologists and biostatisticians with a focus on these diseases. Their historic and recent
efforts have identified new rational treatment targets and moved promising targeted inhibitors from laboratories
into the clinic. Program members also have longstanding interest and contributions in the analysis and
augmentation of host immune responses to lymphoma and myeloma. Engagement with the Cancer Center’s
catchment area (Massachusetts) and training of the next generation of Lymphoma and Myeloma researchers
are integral Program elements.
The Program’s 74 members (47 primary and 27 secondary) represent five DF/HCC institutions and 9 academic
departments. In 2019, peer-reviewed grant funding attributed to the Program was $5.4 million in direct costs
from the NCI and $5.6 million from other sponsors. During the current funding period, primary Program
members published 933 cancer-relevant papers. Of these, 27% were inter-institutional, 23% were intra-
programmatic, and 36% were inter-programmatic collaborations between two or more DF/HCC members.
For the next CCSG finding period, our Specific Aims are to: 1) Elucidate pathogenic mechanisms underlying
specific lymphoid/plasma cell neoplasms; 2) Develop novel therapeutic approaches to lymphoid and plasma
cell neoplasms; and 3) Evaluate early intervention and prevention in patients with precursor conditions for
hematologic malignancies. To realize these Aims, Program members will avail of invaluable CCSG resources:
core facilities, collaborative structures, the CCEE and OCRET functions, and a clinical trials infrastructure that
is highly effective for bench-to-bedside translation.

## Key facts

- **NIH application ID:** 10332550
- **Project number:** 2P30CA006516-57
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** ANTHONY G LETAI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $41,711
- **Award type:** 2
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10332550

## Citation

> US National Institutes of Health, RePORTER application 10332550, Program 06 Lymphoma and Myeloma (2P30CA006516-57). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10332550. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*